The Latest Cardiac and Vascular News
PARIS–(BUSINESS WIRE)–Results from The Atrial Fibrillation Progression Trial (ATTEST), were presented on August 31st at the ESC* Congress 2019 in Paris, France. ATTEST is the first randomised controlled trial to directly compare the effectiveness of ablation using radiofrequency (RF) catheters versus standard antiarrhythmic drugs (AAD) in delaying atrial fibrillation (AF) progression. The results show that patients treated […]
IRVINE, CA, JANUARY 23, 2019 – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias and part of Johnson & Johnson Medical Devices Companies*, announced today the launch of the #UnitedbyVision campaign. Inspired by the ability of the newly-launched CARTO VIZIGO Sheath which allows electrophysiologists to better “see” during procedures […]
IRVINE, Calif., Nov. 29, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its STELLAR** U.S. Investigational Device Exemption (IDE) study. The study will evaluate the safety and effectiveness of HELIOSTAR Multi-electrode […]
IRVINE, Calif., SEPTEMBER 26 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has received approval from the U.S. Food and Drug Administration (FDA) for its VISITAG SURPOINT External Processing Unit and enrollment has begun in its post-market approval study. […]
Multicenter Study to Evaluate Balloon Ablation Catheter for Safety and Effectiveness in Achieving Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation IRVINE, CA, MARCH 15 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled and treated the first […]
IRVINE, CA, — March 13, 2018 — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has completed patient enrollment in its U.S. Investigational Device Exemption (IDE) study of the THERMOCOOL SMARTTOUCH® SF Catheter. The prospective, multicenter, non-randomized study** of 367 […]
IRVINE, Calif., Jan. 11, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled the first patient in the WaveCrest® Investigational Device Exemption (IDE) Trial. The study will evaluate the safety and effectiveness of the WaveCrest® Left Atrial Appendage Occlusion (LAAO) System in […]
DIAMOND BAR, California, March 22, 2017 /PRNewswire/ — Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today the launch of the CARTO VISITAG™ Module with Ablation Index, a new technology providing visual indication based on the integration of power, contact force […]
